Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer

 Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer

Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer

Shots:

  • The P-III FRESCO-2 study involves assessing of fruquintinib vs PBO in patients with m-CRC in ~130 sites across 10 countries
  • The company has initiated the study in the US, EU, and Japan, while the first has been dosed in the US on Sept 03, 2020. The clinical data from P-III FRESCO study in Chinese patients and the global FRESCO-2 study would support NDA submission to the US FDA for patients with advanced m-CRC
  •  EMA & PMDA has reviewed and endorsed the design of FRESCO-2 study. Fruquintinib is a highly selective and VEGFR 1/2/3 inhibitor and has received NMPA’s approval in Sept’2018 and commercially in late Nov’2018 by Eli Lilly under the name Elunate

Click here ­to­ read full press release/ article | Ref: Chi-Med | Image: Oncology News Australia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post